Jan Tennvall
1 – 10 of 93
      - show: 10
 - |
 - sort: year (new to old)
 
        Close
        
            
    
    Embed this list
<iframe src=""
              width=""
              height=""
              allowtransparency="true"
              frameborder="0">
            </iframe>
        - 2024
 - 
                        Mark
        Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE
    
    
- Contribution to journal › Article
 
 - 2022
 - 
                        Mark
        Dosimetric quantities of neuroendocrine tumors over treatment cycles with 177Lu-DOTA-TATE
    
    
- Contribution to journal › Article
 
 - 
                        Mark
        Increased risk of Graves´ophthalmopathy in patients with increasing TRAb after radioiodine treatment and the impact of CTLA4 on TRAb titres
    
    
- Contribution to journal › Article
 
 - 
                        Mark
        Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients
    
    
- Contribution to journal › Article
 
 - 
                        Mark
        Selumetinib Plus Adjuvant Radioactive Iodine in Patients with High-Risk Differentiated Thyroid Cancer : A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)
    
    
- Contribution to journal › Article
 
 - 2021
 - 
                        Mark
        Pituitary function after high-dose 177Lu-DOTATATE therapy and long-term follow-up
    
    
- Contribution to journal › Article
 
 - 2020
 - 
                        Mark
        Substantial intrinsic variability in chemoradiosensitivity of newly established anaplastic thyroid cancer cell-lines
    
    
- Contribution to journal › Article
 
 - 2019
 - 
                        Mark
        The Effect of Radioiodine Treatment on TRAb, Anti-TPO, and Anti-TG in Graves' Disease
    
    
- Contribution to journal › Article
 
 - 2018
 - 
                        Mark
        Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy
    
    
- Contribution to journal › Article
 
 - 2017
 - 
                        Mark
        Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
    
    
- Contribution to journal › Article
 
 
